Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study

Alessandro Giunta; Graziella Babino; Manuela Ruzzetti; Sara Manetta; Sergio Chimenti; Maria Esposito

doi:10.1177/0300060515593254

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study

J Int Med Res. 2016 Sep;44(1 suppl):72-75. doi: 10.1177/0300060515593254.

Authors

Alessandro Giunta¹, Graziella Babino², Manuela Ruzzetti², Sara Manetta², Sergio Chimenti², Maria Esposito²

Affiliations

¹ Department of Dermatology, University of Rome Tor Vergata, Rome, Italy alessandro.giunta@uniroma2.it.
² Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.

Abstract

Aim: To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis.

Methods: Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80 kg or ≥80 kg) and BMI (healthy, BMI 22 - 24.99 kg/m²; overweight, BMI 25 - 29.99 kg/m²; obese, BMI ≥30 kg/m²).

Results: The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n = 12) compared with healthy weight (n = 33) or overweight (n = 21) patients.

Conclusion: Obesity has a negative effect on the efficacy of etanercept in psoriasis.

Keywords: Anti-tumor necrosis factor-α; body mass index; body weight; etanercept; obesity; psoriasis.